|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.
|
31498767 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
|
30835055 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We identified 100 patients (15.9%) with omissions equalling 139 PPOs, and the most common PPOs were due to a lack of angiotensin-converting enzyme inhibitors in patients associated with heart failure or coronary heart disease (n = 23, 16.5%) and a lack of statins (n = 20; 14.4%) and aspirin (n = 20; 14.4%) in coronary heart disease.
|
31573715 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Various medications used in the treatment of HF such as loop diuretics and angiotensin converting enzyme inhibitors have not demonstrated a reduction in sudden cardiac death (SCD); however, beta-blockers (BB) are effective in reducing mortality and SCD.
|
31598875 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy reduced the odds of heart failure events by 29% (0.71, 0.61 to 0.83, P<0.001; I<sup>2</sup>=0%, P=0.78).
|
30296880 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels.
|
31447116 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hypotension risk factors included high healthcare utilisation (proxy measure for HF severity and general comorbidity; eg, ≥10 primary care physician visits versus none, odds ratio (OR): 2.29; 95% CI: 1.34-3.90), previous hypotensive episodes (OR: 2.32; 95% CI: 1.84-2.92), renal failure and use of aldosterone antagonists, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
|
31300503 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common HF medications included beta-blockers (64%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (62%), loop diuretics (46%), digoxin (11%), and aldosterone receptor antagonists (10%).
|
30299591 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin-converting enzyme inhibitors and β-blockers.
|
30724013 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments.
|
30836981 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades.
|
30345485 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusions ARNI distinctly improved left ventricular size and hypertrophy compared with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in HF with reduced EF patients, even after short-term follow-up.
|
31240976 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The advanced heart failure and transplant programme formulated an institutional protocol for initiation of sacubitril/valsartan with defined criteria for switching from angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB).
|
31087629 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.
|
31179336 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We analyzed participants from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) with an available physical examination at baseline.
|
31510768 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to determine the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and follow-up heart failure (HF) according to left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI).
|
30924021 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
A total of 66 patients with heart failure and reduced ejection fraction already on guideline-recommended target dose ACE inhibitors or ARBs (equivalent to enalapril 10 mg twice daily) were switched to maximum-dose sacubitril-valsartan (200 mg twice daily).
|
31772613 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
|
30817783 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found recently that in Ren-2 transgenic hypertensive rats (TGR) addition of soluble epoxide hydrolase inhibitor (sEHi) to treatment with angiotensin-converting enzyme inhibitor (ACEi), surprisingly, increased the mortality due to heart failure (HF) induced by creation of the aorto-caval fistula (ACF).
|
31177795 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs).
|
30931184 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prior studies evaluating thresholds of eGFR decline while using angiotensin-converting enzyme inhibitors in heart failure with reduced ejection have not taken into account this medication-driven decline.
|
31420191 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown.
|
30256890 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
|
30948834 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Cox proportional hazards models adjusted for established clinical risk factors and genomic ancestry tested the independent association of rs9909004 or rs9303504 and the variant interactions with cornerstone HF pharmacotherapies (beta-blockers or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) in additive genetic models.
|
31728800 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
More patients in PARADIGM-HF received an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker than in ANTHEM-HF or SHIFT (100% vs. 85%, P < 0.0001, and 100% vs. 91%, P < 0.001), which was related to PARADIGM's design.
|
31339232 |
2019 |